Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. : HP40-308/2022E-1-PDF
"The objective of this advisory committee statement is to review evidence and develop guidance on strategies to prevent severe consequences of RSV infection in children at high risk of severe RSV disease by administration of monoclonal antibody"--Guidance objective, page 8.
Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.913694&sl=1
| Ministère/Organisme | Canada. National Advisory Committee on Immunization, issuing body. |
|---|---|
| Titre | Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. |
| Type de publication | Monographie |
| Langue | [Anglais] |
| Autres langues publiées | [Français] |
| Édition précédente | Recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants. |
| Format | Électronique |
| Document électronique | |
| Note(s) | Cover title. "Publication date: June 2022." Publication copy replaced 2022-12-12 at request of authors. At head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). Issued also in French under title: Utilisation recommandée du palivizumab pour réduire les complications de l'infection par le virus respiratoire syncytial chez les nourrissons. Includes bibliographical references (pages 76-97). |
| Information sur la publication | [Ottawa] : Public Health Agency of Canada = Agence de la santé publique du Canada, 2022. ©2022 |
| Description | 1 online resource (151 pages) |
| ISBN | 9780660447117 |
| Numéro de catalogue |
|
| Numéro de catalogue du ministère | 220345 |
| Descripteurs | Palivizumab -- Canada. Respiratory syncytial virus -- Canada. Infants -- Diseases -- Canada. |